Translational considerations for immunotherapy clinical trials in pediatric neuro-oncology

While immunotherapy for pediatric cancer has made great strides in recent decades, including the FDA approval of agents such as dinutuximab and tisgenlecleucel, these successes have rarely impacted children with pediatric central nervous system (CNS) tumors. As our understanding of the biological un...

Descripción completa

Detalles Bibliográficos
Autores principales: Foster, Jessica B., Alonso, Marta M., Sayour, Elias, Davidson, Tom B., Persson, Mika L., Dun, Matthew D., Kline, Cassie, Mueller, Sabine, Vitanza, Nicholas A., van der Lugt, Jasper
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2023
Materias:
Pediatric Brain Tumor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232854/
https://www.ncbi.nlm.nih.gov/pubmed/37244226
http://dx.doi.org/10.1016/j.neo.2023.100909

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232854/
https://www.ncbi.nlm.nih.gov/pubmed/37244226
http://dx.doi.org/10.1016/j.neo.2023.100909

Ejemplares similares